Personne :
Ruizmangas, Maria-Gabriela

En cours de chargement...
Photo de profil
Adresse électronique
Date de naissance
Projets de recherche
Structures organisationnelles
Fonction
Nom de famille
Ruizmangas
Prénom
Maria-Gabriela
Affiliation
CHU de Québec-Université Laval
ISNI
ORCID
Identifiant Canadiana
ncf13694601
person.page.name

Résultats de recherche

Voici les éléments 1 - 1 sur 1
  • Publication
    Accès libre
    A collaborative model to implement flexible, accessible and efficient oncogenetic services for hereditary breast and ovarian cancer : the C-MOnGene study
    (MDPI, 2021-05-31) Gekas, Jean; Simard, Jacques; Castonguay, Lysanne; Joly, Yann; Ruizmangas, Maria-Gabriela; Hébert, Johanne; Lapointe, Julie; Chiquette, Jocelyne; Roy, Marie-Claude; Pomey, Marie-Pascale; Desbiens, Christine; Cruz-Mariño, Tania; Dorval, Michel; Touhami, Omar; Brousseau, Claire; Guertin, Jason Robert; Gagnon, Sylvain; Fortier, Sylvain; Lachapelle, Philippe; Rhéaume, Josée.; Gosselin, Isabelle; Côté, Madeleine; Laberge, Maude; Nabi, Hermann; Boisvert, Karine; Poirier, Brigitte; Bouchard, Karine; Roy, Stéphane; Lavoie, Sabrina; Blanchet Saint-Pierre, Arnaud; Beaumont, Martin; Plante, Marie; Sebastianelli, Alexandra; Racine, Marie-Michelle; Renaud, Marie-Claude; Côté, Nathalie; Brisson, Carmen; Charette, Nelson; Faucher, Valérie; Leblanc, Josianne; Dubeau, Marie-Ève
    Medical genetic services are facing an unprecedented demand for counseling and testing for hereditary breast and ovarian cancer (HBOC) in a context of limited resources. To help resolve this issue, a collaborative oncogenetic model was recently developed and implemented at the CHU de Québec-Université Laval; Quebec; Canada. Here, we present the protocol of the C-MOnGene (Collaborative Model in OncoGenetics) study, funded to examine the context in which the model was implemented and document the lessons that can be learned to optimize the delivery of oncogenetic services. Within three years of implementation, the model allowed researchers to double the annual number of patients seen in genetic counseling. The average number of days between genetic counseling and disclosure of test results significantly decreased. Group counseling sessions improved participants' understanding of breast cancer risk and increased knowledge of breast cancer and genetics and a large majority of them reported to be overwhelmingly satisfied with the process. These quality and performance indicators suggest this oncogenetic model offers a flexible, patient-centered and efficient genetic counseling and testing for HBOC. By identifying the critical facilitating factors and barriers, our study will provide an evidence base for organizations interested in transitioning to an oncogenetic model integrated into oncology care; including teams that are not specialized but are trained in genetics.